Analysys Of The Clinical Feature Of COPD Patients With Triple Therapy(ics/laba/lama)

被引：0
|
作者：
Miyazaki, M. [1 ]
Nakamura, H. [2 ]
Sasaki, M. [1 ]
Haraguchi, M. [1 ]
Chubachi, S. [1 ]
Takahashi, S. [1 ]
Yoshida, S. [3 ]
Shirahata, T. [4 ]
Asano, K. [5 ]
Betsuyaku, T. [1 ]
机构：
[1] Keio Univ, Tokyo, Japan
[2] Saitama Med Univ Hosp, Saitama, Japan
[3] Tokyo Med Ctr, Tokyo, Japan
[4] Saitama Social Insurance Hosp, Saitama, Japan
[5] Tokai Univ, Sch Med, Hiratsuka, Kanagawa, Japan
来源：
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2013年 / 187卷
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
A4371
引用
收藏
页数：1
相关论文
共 50 条
  • [41] ARE LABA/LAMA/ICS FDCS A TRIPLE THREAT FOR COPD COMPETITORS IN THE COST-CONSTRAINED EU5?
    Mackin, K.
    Albacker, C.
    Vinuesa, M.
    Cox, J.
    VALUE IN HEALTH, 2017, 20 (09) : A650 - A650
  • [42] Efficacy and Safety of High ICS Dose Fixed-Combination ICS/LABA/LAMA pMDI Compared with ICS/LABA and ICS/LABA plus LAMA in Patients with Uncontrolled Asthma: The TRIGGER Study
    Canonica, G. W.
    Virchow, J.
    Kots, M.
    Zuccaro, F.
    Carzana, E.
    Vele, A.
    Georges, G.
    Petruzzelli, S.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2019, 199
  • [43] Evaluation of Time-to-Triple Therapy in Patients Diagnosed with COPD Initiating Maintenance Therapy with a Fixed-Dose Combination of LAMA/LABA Versus ICS/LABA Within a Large US Health Insurer Database
    Moretz, C.
    Bengtson, L. G. S.
    Sharpsten, L.
    Le, L.
    Koep, E.
    Tong, J.
    Hahn, B.
    Stanford, R. H.
    Asmus, M. J.
    Ray, R.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2019, 199
  • [44] Clinical and Economic Burden of COPD in Patients Poorly Controlled on LABA/LAMA or Inhaled Triple Therapy in Germany - A Retrospective Claims Data Analysis
    Albrecht, I.
    Schild, M.
    Greulich, T.
    Azabdaftari, D.
    Kossack, N.
    Richter, L.
    Meyer, A. C.
    Diesing, J.
    Damm, O.
    Buhl, R.
    Vogelmeier, F.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2024, 209
  • [45] Triple versus LAMA/LABA combination therapy for Japanese patients with COPD: A systematic review and meta-analysis
    Koarai, Akira
    Yamada, Mitsuhiro
    Ichikawa, Tomohiro
    Fujino, Naoya
    Kawayama, Tomotaka
    Sugiura, Hisatoshi
    RESPIRATORY INVESTIGATION, 2022, 60 (01) : 90 - 98
  • [46] Evaluating triple ICS/LABA/LAMA therapies for COPD patients: a network meta-analysis of ETHOS, KRONOS, IMPACT, and TRILOGY studies
    Calzetta, Luigino
    Ritondo, Beatrice Ludovica
    de Marco, Patrizia
    Cazzola, Mario
    Rogliani, Paola
    EXPERT REVIEW OF RESPIRATORY MEDICINE, 2021, 15 (01) : 143 - 152
  • [47] ICS+LABA、LAMA联用与单独使用ICS+LABA对COPD的疗效比较
    梁兴
    张明
    热带医学杂志, 2019, 19 (09) : 1135 - 1138
  • [48] Cost-effectiveness of a single inhaler triple therapy versus ICS/LABA in COPD
    Martin, Alan A.
    Shah, Dhvani
    Goodall, Emma C.
    Schroeder, Melanie
    Risebrough, Nancy
    Ndirangu, Kerigo
    Ismaila, Afisi S.
    EUROPEAN RESPIRATORY JOURNAL, 2018, 52
  • [49] The Overrated Impact of Inhaled Substances (LABA, LAMA, ICS) on Exacerbation Rates in COPD
    Koehler, D.
    Dellweg, D.
    PNEUMOLOGIE, 2018, 72 (02): : 132 - 137
  • [50] Comparative efficacy of inhaled medications (ICS/LABA, LAMA, LAMA/LABA and SAMA) for COPD: a systematic review and network meta-analysis
    Aziz, Mohamed Ismail Abdul
    Tan, Ling Eng
    Wu, David Bin-Chia
    Pearce, Fiona
    Chua, Gerald Seng Wee
    Lin, Liang
    Tan, Ping-Tee
    Ng, Kwong
    INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2018, 13 : 3203 - 3231
12345